The combination of encorafenib and binimetinib in both treatment-naive and previously treated BRAF-mutated NSCLC is currently being evaluated in two phase II trials, the PHAROS (NCT03915951) and ENCO-BRAF trials. Here, BRAF is linked to non-small cell lung carcinoma.